clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Stolte M et al. Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. 1998 Z Gastroenterol pmid:9773482
Adamek RJ and Bethke TD Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. 1998 Am. J. Gastroenterol. pmid:9772056
Stack WA et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. 1998 Am. J. Gastroenterol. pmid:9772054
Mukunda BN et al. Clarithromycin therapy for bacillary peliosis did not prevent bacillary angiomatosis. 1998 Clin. Infect. Dis. pmid:9770180
Laine L et al. Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. 1998 Aliment. Pharmacol. Ther. pmid:9768532
Louw JA et al. Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. 1998 Aliment. Pharmacol. Ther. pmid:9768531
Pipkin GA et al. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9768524
Horgen L et al. Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. 1997 Res. Microbiol. pmid:9765852
Heald AE et al. Taste and smell complaints in HIV-infected patients. 1998 AIDS pmid:9764787
Mégraud F and Doermann HP Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. 1998 Gut pmid:9764043
Hawkey CJ et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. 1998 Lancet pmid:9759744
Pontani D et al. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. 1998 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9758284
Kubas G and Gospodarek T [The use of clarithromycin and amoxycillin in pediatric acute otitis media]. 1997 Otolaryngol Pol pmid:9757683
Denys A [Theoretical basis for the antibiotic therapy of the upper part of the respiratory system]. 1997 Otolaryngol Pol pmid:9757681
Greenblatt DJ et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. 1998 Clin. Pharmacol. Ther. pmid:9757151
Debets-Ossenkopp YJ et al. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9756790
Gikas A et al. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9756789
Apseloff G et al. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. 1998 J Clin Pharmacol pmid:9753212
Huang WH et al. New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection. 1998 Zhonghua Yi Xue Za Zhi (Taipei) pmid:9745160
Hiratsuka T et al. [Severe bronchorrhea accompanying alveolar cell carcinoma: treatment with clarithromycin and inhaled beclomethasone]. 1998 Nihon Kokyuki Gakkai Zasshi pmid:9742869
Sevin E et al. Co-detection of Helicobacter pylori and of its resistance to clarithromycin by PCR. 1998 FEMS Microbiol. Lett. pmid:9742711
Siu LK et al. Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for Helicobacter pylori. 1998 J. Clin. Microbiol. pmid:9738066
Alder JD et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. 1998 Antimicrob. Agents Chemother. pmid:9736568
Lamouliatte H et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. 1998 Am. J. Gastroenterol. pmid:9732938
Chu KM et al. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. 1998 Am. J. Gastroenterol. pmid:9732921
Vakil N et al. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. 1998 Am. J. Gastroenterol. pmid:9732920
Lanza FL et al. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. 1998 Helicobacter pmid:9731994
Bazzoli F et al. Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. 1998 Helicobacter pmid:9731991
Graham DY et al. Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection. 1998 Helicobacter pmid:9731987
Barzilai A et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. 1998 Scand. J. Infect. Dis. pmid:9730300
Gorski JC et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. 1998 Clin. Pharmacol. Ther. pmid:9728893
Bermudez LE et al. Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice. 1998 J. Infect. Dis. pmid:9728568
Bayoumi AM and Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. 1998 AIDS pmid:9727572
Harris AW et al. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. 1998 Aliment. Pharmacol. Ther. pmid:9726387
Pazzi P et al. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. 1998 Aliment. Pharmacol. Ther. pmid:9726385
Sung JJ et al. One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9726384
Nelson KG et al. Results of operation in Mycobacterium avium-intracellulare lung disease. 1998 Ann. Thorac. Surg. pmid:9725364
Venuta A et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. 1998 Jun-Jul J. Int. Med. Res. pmid:9718470
Tanahashi T et al. Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy. 1998 J. Gastroenterol. Hepatol. pmid:9715426
Cecchi R and Torelli E Schönlein-Henoch purpura in association with duodenal ulcer and gastric Helicobacter pylori infection. 1998 J. Dermatol. pmid:9714985
Améndola R et al. [Is dental plaque a normal Helicobacter pylori reservoir?]. 1998 Acta Gastroenterol. Latinoam. pmid:9713656
Bergmann JS and Woods GL In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. 1998 Int. J. Tuberc. Lung Dis. pmid:9712275
Fernández Bermejo M and García Grávalos R [Ebrotidine in the eradicating treatment of H. pylori]. 1998 Jun-Jul Gastroenterol Hepatol pmid:9711019
Burman WJ et al. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. 1998 AIDS pmid:9708410
van der Wouden EJ et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. 1998 Am. J. Gastroenterol. pmid:9707042
Wang G et al. Genotypic characterization of clarithromycin-resistant and -susceptible Helicobacter pylori strains from the same patient demonstrates existence of two unrelated isolates. 1998 J. Clin. Microbiol. pmid:9705423
Ellenrieder V et al. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9701524
Takizawa H et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. 1998 Eur. Respir. J. pmid:9701415
Fennerty MB et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. 1998 Aug 10-24 Arch. Intern. Med. pmid:9701099
Hsieh PF et al. Molecular mechanisms of clarithromycin resistance in Helicobacter pylori. 1998 J. Formos. Med. Assoc. pmid:9700240